A Phase 4 interventional study of Duloxetine and Placebo in Knee Osteoarthritis, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 2 sites in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Sunnybrook Health Sciences Centre · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing duloxetine in Osteoarthritis, Knee — 4 open to participants now, 4 under way, none of them phase 3. duloxetine · Osteoarthritis, Knee.
Among the 19 studies testing duloxetine in Osteoarthritis, Knee, this one is the 8th largest by planned enrollment, is one of 2 that started in 2024, is one of 6 in phase 4, and was the 17th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →4 of the 19 studies testing duloxetine in Osteoarthritis, Knee are open now, in 2 countries. Recruiting first, the newest first:
Benedict Alter · Sites in United States
Ages 45–80
Northwestern University · Sites in United States
Ages 41+
VA Office of Research and Development · Sites in United States
Ages 40+ · Healthy volunteers
By country, each count listing its studies:
duloxetine: first FDA approval 2004 (CYMBALTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7 · Phase 4 6
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 102 across the 19 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Sunnybrook Health Sciences Centre has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
1 of the studies testing duloxetine in Osteoarthritis, Knee that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423716Sunnybrook Health Sciences CentreEffect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE) | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing duloxetine in Osteoarthritis, Knee, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Knee replacement surgery for osteoarthritis is a commonly performed procedure in Canada with 75,000 of these surgeries performed each year. Success rate for knee replacement surgery is high but more than 20% of patients are still dissatisfied mainly due to reports of ongoing pain. Pain control following knee surgery is important in order to allow patients to engage in recovery and rehabilitation. The current standard of pain management after surgery centers around the use of opioids which is a concerning practice as highlighted by the opioid epidemic. Duloxetine is an antidepressant that has pain relieving properties and it has been studied in patients undergoing knee replacement surgery. Studies to date have not been designed optimally to demonstrate the full effects of opioid dose reduction and the use of duloxetine as a medication following knee replacement surgery. This research study seeks to start duloxetine before surgery, at the recommended therapeutic dose, and for the duration of the early rehabilitation period. If the study is successful, this low-cost medication can improve satisfaction rates and change the standard way the pain management is typically carried out for patients undergoing the knee replacement surgery.
The use of duloxetine around the time of total knee arthroplasty has emerged as a promising intervention to help with pain management after surgery and in particular as an opioid sparing agent. Duloxetine is an antidepressant with serotonin and norepinephrine reuptake inhibition effects that also independently exerts an analgesic effect. Duloxetine is Health Canada approved for several indications including pain arising from osteoarthritis of the knee. Pain inhibition action of duloxetine is believed to be a result of potentiation of descending inhibitory pain pathways within the central nervous system. Existing studies examining duloxetine use at the time of surgery has demonstrated statistically significant but less clinically meaningful impacts on opioid sparing and pain reduction. The deficiencies in study design of existing studies have either underdosed duloxetine (30mg instead of the recommended 60mg) and/or utilized non-standard duration of therapy (started too late, continued for only 2 weeks). This study seeks to definitively address whether duloxetine administered 2 weeks preoperatively at 60mg once daily, in addition to standard analgesic practice, will decrease opioid consumption at 1 week postoperatively.
Prospective, randomized, blinded (investigators, clinicians, participant, data collectors/analysts) trial.
Primary Outcome
•Cumulative opioid consumption at 1 week post-operatively.
Secondary Outcomes
Interventional medication supply: Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.
Standard of care: On the day of surgery, participants will be premedicated with acetaminophen (1000mg) and celecoxib (400mg). Per standard of care, all participants will receive an ultrasound guided adductor canal catheter (bolus ropivacaine 0.5% 10ml). This will be followed by a spinal anesthetic with mepivacaine 2% 3ml and 10mcg of fentanyl. Intraoperative sedation will consist of a propofol infusion titrated to SAS (Sedation Agitation Scale) of 3-4.
All TKAs will be performed using a standard medial parapatellar approach and the same cemented total knee system. Tourniquet will be applied and used as part of the case. Periarticular local infiltration will be used per standard practice using ropivacaine 0.2% with 1:200 000 epinephrine up to 50ml.
Post-surgery: Participants will be evaluated on POD-0, POD-1 and POD-2 while in hospital or at home through phone call and at 1, 6, and 12 weeks.
Participant satisfaction will be assessed using the Patients' Global Impression of Change (PGIC) Scale at 1, 6, and 12 weeks post-surgery.
Pain scores and opioid consumption will be recorded daily for 1 week post-operatively.
Patients will record their pain and opioid consumption on a weekly basis until week 12 post-operatively.
Physical function, emotional function, and presence of neuropathic pain will be collected at 6 and 12 weeks.
Active and passive range of motion will be assessed by orthopedic surgeon using goniometer at 6 (+/-1 week) and 12 (+/-1 week) weeks and 4.5 month (+/-2 weeks) postoperatively.
Group 1: Intervention Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.
Group 2: Control Placebo OD for 2 weeks preoperatively then OD for 6 weeks post-surgery.
Both Groups:
On the day of surgery, standard post-anesthetic care unit (PACU) orderset will be employed and the postoperative analgesic regimen will follow standard of care including: acetaminophen 1g QID, celecoxib 200mg BID, and hydromorphone 1-3mg PO q2h PRN.
Participants will be discharged on POD-0, POD-1 or POD-2 with acetaminophen 1000mg TID, celecoxib 100mg BID, and hydromorphone (2-4mg PO q4h PRN). Patients for same-day discharge (POD-0) will have ACB catheter bolus of 10cc of 0.5% ropivacaine prior to removal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of to study drug use:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.
Drug: Duloxetine
Placebo OD for 2 weeks preoperatively then OD for 6 weeks post-surgery.
Drug: Placebo
60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
Opioid consumption
Cumulative opioid consumption at 1 week post-operatively
Time frame: Cumulative opioid consumption at 1 week post-operatively
Nausea/vomiting
Presence of nausea or vomiting
Time frame: 12 weeks (i.e., duration of study)
Pain at rest and with activity
Maximum pain score on 0-10 Likert Scale (NRS)
Time frame: 10-14 days preoperative; 1,6,12 weeks and 4.5 months
Additional analgesic use
Anti-neuropathic medications
Time frame: 8 weeks (i.e., duration of study)
Additional analgesic use: opioid prescription
Family physician or orthopaedic surgeon opioid prescription
Time frame: 8 weeks (i.e., duration of study)
Physical function measured by BPI
Brief Pain Inventory
Time frame: Preoperative, 6, 12 weeks and 4.5 months
Physical function measured by Oxford Knee Scale
Oxford Knee Scale
Time frame: Preoperative, 6, 12 weeks and 4.5 months
Range of motion: Physical function
Time frame: Preoperative, 6, 12 weeks and 4.5 months
Emotional function measured by GAD-7
GAD-7
Time frame: Preoperative, 6, 12 weeks and 4.5 months
Emotional function measured by PHQ-9
PHQ-9
Time frame: Preoperative, 6, 12 weeks and 4.5 months
Patient satisfaction
Patient global impression of change (PGIC)
Time frame: 1 week after start of intervention; 1, 6, and 12 weeks after surgery and 4.5 months after surgery
Neuropathic pain
Presence of neuropathic pain (S-LANSS)
Time frame: 6 and 12 weeks post-surgery
Chronic post-surgical pain
Presence of chronic post-surgical pain (based on NRS \> 0)
Time frame: 12 weeks post-surgery
Quality of recovery (QoR-15)
Change in Quality of Recovery-15 (QoR-15) score, a 15-item patient-reported questionnaire assessing postoperative recovery across pain, physical comfort, physical independence, psychological support, and emotional state.
Time frame: 1/6/12 weeks and and 4.5 months post-surgery
Adverse events
Adverse events relating to study medication (dizziness, drowsiness, nausea, vomiting, insomnia)
Time frame: 1 week after starting intervention; in hospital at POD1-3, and 1, 6, and 12 weeks post-op.
Plan to share: Yes — De-identified data will be available upon request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Upon publication, no limit on time
Access criteria: Contact study investigators
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 32 months after the start.
Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 32 months is above that.
Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duloxetine
Sunnybrook Health Sciences Centre →